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ANTI-MOG ANTIBODIES ARE FREQUENTLY
ASSOCIATED WITH STEROID-SENSITIVE
RECURRENT OPTIC NEURITIS
Optic neuritis (ON) is an inflammatory disease of the
optic nerve characterized by pain and visual loss and
often associated with multiple sclerosis (MS) or neu-
romyelitis optica spectrum disorders (NMOSD).
Recent evidence suggests that certain forms of ON
are associated with anti–myelin oligodendrocyte gly-
coprotein (MOG) antibodies.1–4
A distinct clinical subset of ON is characterized by
multiple episodes that involve one or both optic nerves,
occur within months or weeks, and do not involve any
other associated clinical or radiologic findings. This
entity, defined as either recurrent optic neuritis
(rON) or chronic relapsing inflammatory optic neuritis
(CRION),5 is typically corticosteroid-responsive and
corticosteroid-dependent, often requiring immuno-
suppressive therapy for corticosteroid-sparing effect.
Our aim was to determine whether aquaporin-4
(AQP4)-negative patients with ON harbor antibodies
to MOG and whether anti-MOG antibodies are clin-
ically relevant.
Methods. We examined sera from 111 patients ini-
tially referred to our diagnostic service for AQP4 test-
ing. These patients had at least one episode of
unilateral or bilateral ON, as reported by their referring
physicians. All 111 patients were APQ4-negative.
Twelve patients with primary progressive MS and 30
patients with relapsing-remitting MS (RRMS) were
used as disease controls. The Ethics Committee of
the University of Athens granted ethical approval.
Anti-MOG screening was performed using a cell-
based-assay (CBA). Patient sera (1:60 dilution) were
applied on live human embryonic kidney 293T cells
and transiently transfected with full-length MOG
enhanced green fluorescent protein followed by a goat
anti-human secondary antibody (Alexa Fluor 568).
Positive samples were retested and titrated in a
blinded fashion by M.R.
To investigate optic nerve specificity, anti-MOG–
positive sera were applied onto 10 mm nonfixed or
2% paraformaldehyde-fixed sections of fresh frozen
human optic nerves (Netherlands Brain Bank,
Amsterdam). A commercial monoclonal anti-MOG
antibody was used as a positive control (Millipore,
Billerica, MA; clone 8–18C5).
Results. Anti-MOG antibodies were detected by
CBA in 8/111 AQP4-seronegative patients and in
0/42 MS disease controls (figure 1, B–D). All 8
MOG-positive patients had at least one episode of
ON, and 5 of them fulfilled the criteria for rON/
CRION (defined as $3 episodes of ON within a
period of a few months to a year). Fifteen of 30
patients with RRMS had at least one episode of
ON, and 10 of the 15 had a relapsing ON course.
The 5 patients with rON/CRION (followed by
M.C.D. for 2–11 years) had recurrent disease con-
fined to optic nerves, often associated with or pre-
ceded by pain. Brain/orbital MRI or CSF analyses
were normal except for optic nerve enhancement in
2 patients. Spinal MRI depicted one small subclinical
chronic lesion in the cervical spine in one of the
patients who never developed any clinical symptoms
of myelitis. Antibody titers did not correlate with
disease severity or number of relapses (figure 1A).
All received IV steroids during the early attacks, but
they were subsequently maintained on a low-dose oral
regimen. In 2 patients, the attacks occurred very fre-
quently when the oral corticosteroid dose was lowered
below 15–20 mg every other day, necessitating the
concurrent administration of an immunosuppressant
such as mycophenolate mofetil. One patient with
multiple episodes over many years who eventually
developed optic atrophy in one eye also received rit-
uximab without success; relative stability (only 1 or 2
episodes yearly) was induced by bimonthly plasma-
pheresis (figure e-1 at Neurology.org/nn).
As human MOG antibodies do not recognize
paraffin-fixed denaturated epitopes,6 we used fresh-
frozen, nonfixed, or lightly fixed human optic nerve
tissue as substrate. No specific binding of the patients’
sera or IgG was observed (figure e-2A).
Discussion. We have characterized and longitudi-
nally followed up 5/8 patients with anti-MOG–
positive rON/CRION without spinal cord or brain
symptomatology These patients do not fall within the
rubric of NMOSD, and our follow-up revealed that
relapses were confined to the optic nerves and
were highly sensitive to even low doses of oral
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corticosteroids. Our results confirm recent
observations3,4 that anti-MOG antibodies are
frequently associated with recurrent forms of ON.
Anti-MOG antibodies have also been associated
with pediatric inflammatory demyelinating diseases,
including acute disseminated encephalomyelitis.7 A
comparative epitope mapping of MOG antibodies
from different syndromes identified a dominant
MOG epitope but failed to elucidate a causative rela-
tionship or define distinct clinical phenotypes.6 No
binding of patients’ sera was observed in our optic
nerve preparations, in which native epitopes are pre-
served. Whether the rON-associated anti-MOG anti-
bodies are pathogenic, causing conduction block in
the optic nerve, demyelination, or edema, remains
unclear.
Our observations suggest that anti-MOG antibod-
ies are frequently associated with the rON/CRION
phenotype, which is a highly steroid-responsive disor-
der. Although the rON series is small, the finding is
supported by the observation that all of the RRMS
control patients with ON were MOG-seronegative.
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Figure 1 Clinical characteristics and antibody profile of patients
(A) Clinical characteristics of myelin oligodendrocyte glycoprotein (MOG)-positive patients with recurrent optic neuritis (rON). (B–D) Cell-based assay of a
representative patient. (B) MOG– enhanced green fluorescent protein (EGFP) transfected human embryonic kidney 293T cells. (C) Immunostaining with
serum of a representative patient with rON on live non-permeabilized MOG-EGFP transfected cells. (D) Merged immunofluorescence image that shows
colocalization. Scale bar 5 100 mm. CS 5 corticosteroids; IVIg 5 IV immunoglobulin; ON 5 optic neuritis; PE 5 plasma exchange.
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